Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463).
暂无分享,去创建一个
Steve Y. Cho | K. Kelly | T. Horton | T. Henderson | S. Parsons | S. Castellino | D. Hodgson | B. Hoppe | Q. Pei | Yue Wu | F. Keller | A. Punnett | K. Mccarten | Hema Kishore Dave